Sandra Catlin, APRN
Family · Falls City, NENPI 1447205760
Payments from drug & device makers
Across 231 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$739
- Novo Nordisk$248
- Otsuka America Pharmaceutical, Inc.$224
- Neurocrine Biosciences, Inc.$127
- Lilly USA, LLC$119
- plus $934 from 23 others
What the payments were for
- Food & beverage$3,430100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 77 | $1,038 |
| Amgen | 61 | $739 |
| Novo Nordisk | 13 | $248 |
| Otsuka America Pharmaceutical, Inc. | 13 | $224 |
| Neurocrine Biosciences, Inc. | 8 | $127 |
| Lilly USA, LLC | 8 | $119 |
| Pfizer | 7 | $103 |
| Vanda Pharmaceuticals Inc. | 5 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $85 |
| Novartis | 4 | $78 |
| Bayer | 1 | $76 |
| Corcept Therapeutics | 1 | $66 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Axsome Therapeutics, Inc. | 4 | $57 |
| Mylan Specialty L.p. | 2 | $41 |
| Boehringer Ingelheim | 3 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Acadia Pharmaceuticals Inc | 2 | $28 |
| Boston Scientific | 1 | $22 |
| Nevro Corp. | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Biogen | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Hologic Sales And Service, LLC | 1 | $14 |
How this compares
$3,430 in reported general payments places this provider in the 90th percentile of 809 family providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 133 | $101,975 |
| EliquisApixaban | 113 | $64,511 |
| OzempicSemaglutide | 47 | $45,301 |
| RexultiBrexpiprazole | 31 | $39,544 |
| VraylarCariprazine Hcl | 21 | $30,371 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $24,355 |
| FarxigaDapagliflozin Propanediol | 11 | $16,989 |
| RybelsusSemaglutide | 16 | $16,868 |
| TrulicityDulaglutide | 15 | $16,516 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $14,622 |
| QuliptaAtogepant | 12 | $13,239 |
| MounjaroTirzepatide | 12 | $13,000 |
| XareltoRivaroxaban | 11 | $12,995 |
| Repatha SureclickEvolocumab | 22 | $12,098 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $9,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $38 | $101,975133 claims |
| PfizerEliquis, Lyrica | $103 | $67,734124 claims |
| Novo NordiskOzempic, Rybelsus | $248 | $62,16963 claims |
| AbbVieVraylar, Qulipta | $1,038 | $43,60933 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $224 | $39,54431 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $119 | $29,51627 claims |
| Johnson & JohnsonXarelto | $16 | $12,99511 claims |
| NovartisEntresto | $78 | $6,86715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Nebraska.
Other family in Falls City
- Kylee MeyerFalls City$4K
- Chantel CollierFriend$257K
- Stephanie SimonOmaha$157K
- Rebecca NewberryOmaha$156K
- Michelle BrtekzwienerNorfolk$59K
- Angela CraigOmaha$35K
- Laura FalconeOmaha$26K
- Ladeana SmedlundBoys Town$21K
- Brittany MatneyOmaha$14K
- Patricia TeeterWahoo$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.